View Clinical Trial (Medical Research Study)

A Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia - NCT01179217-11215(Clinical Trial 722220)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Brooklyn
State:  
NY
Zip Code: 11215
Conditions: Sickle Cell Anemia - Sickle ß0-Thalassemia
Purpose: The purpose of this research is to test the effects of L-glutamine on red blood cells of patients with Sickle Cell Anemia or Sickle ß0-Thalassemia. Glutamine is a part of protein and is a part of a person's normal diet. It is often used as a nutritional supplement or as medication for various medical problems such as intestinal problems. The benefits of participating in this study may be a decrease in pain and other problems caused by sickle cell disease.
Study summary:
Criteria: Inclusion Criteria: - Patient is at least five years of age. - Patient has been diagnosed with sickle cell anemia or sickle ß°-thalassemia (documented by hemoglobin electrophoresis). - Patient has had at least two documented episodes of sickle cell crises within 12 months of the screening visit. - If the patient has been treated with an anti-sickling agent within three months of the screening visit, the therapy must have been continuous for at least three months with the intent to continue for the duration of the study. - Patient or the patient's legally authorized representative has given written informed consent. - if the patient is a female of child-bearing potential, she agrees to avoid pregnancy during the study and is willing and agrees to practice a recognized form of birth control during the course of the study (e.g. barrier, birth control pills, abstinence). Exclusion Criteria: - Patient has a significant medical condition that required hospitalization (other than sickle cell crisis) within two months of the screening visit. - Patient has prothrombin time INR > 2.0. - Patient has serum albumin < 3.0 g/dl. - Patient has received any blood products within three weeks of the Screening Visit. - Patient has a history of uncontrolled liver disease or renal insufficiency (refer to Appendix 3 for guidelines). - Patient is pregnant or lactating or has the intention of becoming pregnant during the study (if female and of child-bearing potential). - Patient has been treated with an experimental anti-sickling medication/ treatment within 30 days of the screening visit (with the exception of hydroxyurea in pediatric patients). - Patient is currently taking or has been treated with an investigational drug within 30 days of the screening visit (with the exception of hydroxyurea in pediatric patients). - Patient is currently enrolled in an investigational drug or device study and/or has participated in such a study within 30 days of the screening visit. - There are factors that would, in the judgment of the investigator, make it difficult for the patient to comply with the requirements of the study.
Study is available at: New York Methodist Hospital - SC/Thalassemia Program
Brooklyn, NY 11215
United States

Primary Contact:
Geraldine Ciaravalo
Email: gec9038@nyp.org
Phone: 718-857-5643

Secondary Contact:
Sarah L. Grimberg
Email: sarah.grimberg@clindatrix.com
Phone: (949) 428-6625
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 23, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.